Form 4: Prelude Therapeutics Director Martin Babler Granted 38,000 Stock Options

Prelude Therapeutics Inc. director Martin Babler was granted 38,000 stock options with an exercise price of $1.04 per share, aligning his interests with shareholder value.

Summary

• Martin Babler, a Director of Prelude Therapeutics Inc. (PRLD), was granted 38,000 Director Stock Options.
• The transaction date for this grant was June 12, 2025.
• Each option has an exercise price of $1.04.
• The options were granted at a price of $0.00 per derivative security, indicating they were awarded as compensation.
• The options will fully vest upon the earlier of the Issuer's next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), contingent on Mr. Babler's continued service.
• The expiration date for these options is June 11, 2035.
• Following this transaction, Martin Babler beneficially owns 38,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholder value, which is generally viewed favorably. However, it is a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of stock options to Director Martin Babler helps align his financial interests with those of the company's shareholders, incentivizing long-term value creation.
• The options have a long expiration date (June 11, 2035), providing a significant window for potential value realization.

Future Outlook

The granted stock options are subject to a future vesting schedule, which will occur upon the earlier of the Issuer's next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), provided the reporting person continues to provide service to the Issuer.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across publicly traded companies in various industries to incentivize leadership and align their interests with long-term shareholder value. It does not provide specific insights into broader industry trends beyond standard compensation practices.

Comparison to Industry Standards

• NA A Form 4 filing primarily reports individual transactions and does not typically provide sufficient context or data for a detailed comparison of compensation packages against specific industry benchmarks or comparable companies. Such an assessment would require a review of the company's full compensation policies and peer group data, which are not included in this document.

Related Party Transactions

• The grant of 38,000 stock options to Martin Babler, a director of Prelude Therapeutics Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders by incentivizing long-term company performance and stock appreciation.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The stock options will vest upon the earlier of Prelude Therapeutics Inc.'s next annual stockholder meeting or June 12, 2026, subject to Martin Babler's continued service.

Key Dates

Keywords

SEC Form 4, stock options, director compensation, Prelude Therapeutics, PRLD, beneficial ownership, equity compensation, corporate governance